Bid­ding war erupts over Di­men­sion’s gene ther­a­py pipeline as Ul­tragenyx coun­ters Re­genxbio deal

A bid­ding war has sud­den­ly erupt­ed over one of the most dam­aged biotechs in gene ther­a­py R&D.

Just weeks af­ter Re­genxbio lined up the ac­qui­si­tion of Di­men­sion Ther­a­peu­tics $DMTX for $86 mil­lion in stock, Ul­tragenyx $RARE has come along with an of­fer of $5.50 a share, sig­nif­i­cant­ly more than what Re­genxbio $RGNX had of­fered ($3.41) and a 358% pre­mi­um over what Di­men­sion’s shares were trad­ing for ahead of the ear­li­er buy­out an­nounce­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.